Prognostic significance of CD30 expression in nasal natural killer/T‑cell lymphoma

Wang,Guan‑Nan; Zhao,Wu‑Gan; Li,Ling; Zhang,Dan‑Dan; Gao,Xian‑Zheng; Zhou,Jun; Zhang,Lei; Fu,Xiao‑Rui; Zheng,Xiang‑Yu; Li,Ye; Li,Zhen; Zhang,Ming‑Zhi; Li,Wen‑Cai

doi:10.3892/ol.2017.5592

Prognostic significance of CD30 expression in nasal natural killer/T‑cell lymphoma

Authors:
- Guan‑Nan Wang
- Wu‑Gan Zhao
- Ling Li
- Dan‑Dan Zhang
- Xian‑Zheng Gao
- Jun Zhou
- Lei Zhang
- Xiao‑Rui Fu
- Xiang‑Yu Zheng
- Ye Li
- Zhen Li
- Ming‑Zhi Zhang
- Wen‑Cai Li
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 11, 2017 https://doi.org/10.3892/ol.2017.5592
Pages: 1211-1215
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of tumor necrosis factor receptor superfamily member 8 (CD30) in extranodal natural killer/T‑cell lymphoma (ENKTL) using immunohistochemistry, and to evaluate the association between CD30 and clinicopathological and prognostic significance. CD30 expression was detected using immunohistochemistry on paraffin‑embedded sections obtained from 122 patients with ENKTL prior to treatment. In total, 70 of these patients with complete clinical data were collected for prognostic analysis. The level of CD30 expression, of the 122 patients with ENKTL, was grouped on the basis of a 5‑tiered scale as follows: 0%, no staining; 1+, <25% positive cells; 2+, 25‑50% positive cells; 3+, 50‑75% positive cells; and 4+, >75% positive cells). In total, 36 (29.5%) were classified as 0; 46 (37.7%) as 1+; 22 (18.0%) as 2+; 12 (9.8%) as 3+; and 6 (4.9%) as 4+. Among the 86 patients with scores between 1+ and 4+, the membranous staining patterns of CD30 expression were sporadic (33.7%), focal (43.2%), diffuse (15.1%) and angiocentric (8.1%). When considering a score of ≥3+ as CD30 positivity (CD30+), the CD30+ group had significantly shorter overall survival rates (P=0.0023) and progression‑free survival rate (P=0.0008) compared with CD30 negative group. However, no statistically significant association was found between CD30 expression and clinicopathological features (P<0.05). The present study found that the expression of CD30 (≥3+) was significantly associated with poor prognosis but was not associated with clinical and histopathological parameters in ENKTL. Therefore, CD30 may be a useful prognostic marker in ENKTL.

View Figures

View References

1	Swerdlow SH, Campo E, Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW: World Health Organization classification of tumors of hematopoietic and lymphoid tissues. 4th. IARC; Lyon, France: 2008
2	Li XQ, Li GD, Gao ZF, Zhou XG and Zhu XZ: The Chinese Lymphoma Study Group: Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of 10,002 cases. J Diagn Concepts Pract. 11:111–115. 2012.
3	Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO and Liang R: Clinical differences between nasal and extranasal natural killer⁄T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 113:3931–3937. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kim TM and Heo DS: Extranodal NK/T-cell lymphoma, nasal type: New staging system and treatment strategies. Cancer Sci. 100:2242–2248. 2009. View Article : Google Scholar : PubMed/NCBI
5	Oshimi K, Kawa K, Nakamura S, Suzuki R, Suzumiya J, Yamaguchi M, Kameoka J, Tagawa S, Imamura N, Ohshima K, et al: NK-cell neoplasms in Japan. Hematology. 10:237–245. 2005. View Article : Google Scholar : PubMed/NCBI
6	Ye Z, Cao Q, Niu G, Liang Y, Liu Y, Jiang L, Yu X and Han A: p63 and p53 expression in extranodal NK/T cell lymphoma, nasal type. J Clin Pathol. 66:676–680. 2013. View Article : Google Scholar : PubMed/NCBI
7	Wang H, Wang L, Liu WJ, Xia ZJ, Huang HQ, Jiang WQ, Li ZM and Lu Y: High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. Oncotarget. 7:3035–3345. 2016.
8	Wang H, Li P, Zhang X, Xia Z, Lu Y and Huang H: Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Oncol Lett. 12:825–836. 2016.PubMed/NCBI
9	Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ and Inghirami G: CD30 in normal and neoplastic cells. Clin Immunol. 90:157–164. 1999. View Article : Google Scholar : PubMed/NCBI
10	Deutsch YE, Tadmor T, Podack ER and Rosenblatt JD: CD30: An important new target in hematologic malignancies. Leuk Lymphoma. 52:1641–1654. 2011. View Article : Google Scholar : PubMed/NCBI
11	Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, Zinzani PL and Pileri SA: CD30 expression in peripheral T-cell lymphomas. Haematologica. 98:e81–e82. 2013. View Article : Google Scholar : PubMed/NCBI
12	Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, Martin A, Fabiani B, Delarue R, Tournilhac O, et al: Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: High correlation with mRNA levels. Blood. 124:2983–2986. 2014. View Article : Google Scholar : PubMed/NCBI
13	Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, Raffeld M and Jaffe ES: Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: Both EBV-positive and EBV-negative variants exist. Am J Surg Pathol. 37:816–826. 2013. View Article : Google Scholar : PubMed/NCBI
14	Duvic M: CD30+ neoplasms of the skin. Curr Hematol Malig Rep. 6:245–250. 2011. View Article : Google Scholar : PubMed/NCBI
15	Gaal K, Sun NC, Hernandez AM and Arber DA: Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol. 24:1511–1517. 2000. View Article : Google Scholar : PubMed/NCBI
16	Kuo TT, Shih LY and Tsang NM: Nasal NK/T cell lymphoma in Taiwan: A clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol. 12:375–387. 2004. View Article : Google Scholar : PubMed/NCBI
17	Li P, Jiang L, Zhang X, Liu J and Wang H: CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. BMC Cancer. 14:8902014. View Article : Google Scholar : PubMed/NCBI
18	Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim CW and Jeon YK: Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 56:1778–1786. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hong J, Park S, Baek HL, Jung JH, Kang IG, Sym SJ, Park J, Ahn JY, Cho EK, Kim ST, et al: Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol. 5:939–947. 2012.PubMed/NCBI
20	Li T, Zhang B, Ye Y and Yin H: Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas. Hum Pathol. 37:54–60. 2006. View Article : Google Scholar : PubMed/NCBI
21	Schwartz EJ, Molina-Kirsch H, Zhao S, Marinelli RJ, Warnke RA and Natkunam Y: Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: An analysis of 84 cases. Am J Clin Pathol. 130:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
22	Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS and Kim SW: Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer. 89:2106–2116. 2000. View Article : Google Scholar : PubMed/NCBI
23	Lu D, Lin CN, Chuang SS, Hwang WS and Huang WT: T-cell and NK/T-cell lymphomas in southern Taiwan: A study of 72 cases in a single institute. Leuk Lymphoma. 45:923–928. 2004. View Article : Google Scholar : PubMed/NCBI
24	Ramos-Vara JA and Miller MA: Comparison of two polymer-based immunohistochemical detection systems: ENVISION+ and ImmPRESS. J Microsc. 224:135–139. 2006. View Article : Google Scholar : PubMed/NCBI
25	Oshimi K: Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 139:532–544. 2007. View Article : Google Scholar : PubMed/NCBI
26	Mraz-Gernhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S and Kim YH: Natural killer/natural killer-like T-cell lymphoma, CD56, presenting in the skin: An increasingly recognized entity with an aggressive course. J Clin Oncol. 19:2179–2188. 2001.PubMed/NCBI
27	Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, et al: CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 121:2715–2724. 2013. View Article : Google Scholar : PubMed/NCBI
28	Bisig B, de Reyniès A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, Delsol G, Lamant L, Gaulard P and de Leval L: CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 98:1250–1258. 2013. View Article : Google Scholar : PubMed/NCBI